Y Intercept Hong Kong Ltd Takes $81,000 Position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Y Intercept Hong Kong Ltd acquired a new position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 14,973 shares of the company’s stock, valued at approximately $81,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in DiaMedica Therapeutics by 29.6% during the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after purchasing an additional 70,070 shares during the last quarter. Blue Trust Inc. increased its position in shares of DiaMedica Therapeutics by 56.2% during the fourth quarter. Blue Trust Inc. now owns 69,122 shares of the company’s stock worth $375,000 after buying an additional 24,875 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in DiaMedica Therapeutics during the third quarter worth $40,000. 10.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.

DiaMedica Therapeutics Stock Up 0.5 %

DiaMedica Therapeutics stock opened at $6.08 on Thursday. The company has a market capitalization of $259.99 million, a PE ratio of -10.86 and a beta of 1.52. The firm’s fifty day moving average is $5.89 and its 200 day moving average is $4.97. DiaMedica Therapeutics Inc. has a 12-month low of $2.14 and a 12-month high of $6.82.

DiaMedica Therapeutics Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.